ArticleTranslational lung cancer research2025
Pre-screening value of serum albumin and the glucose-lymphocyte ratio as the "transport-activation" effectors of immune checkpoint inhibitors in small cell lung cancer.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Safety evaluation of Sodium-glucose cotransporter 2 inhibitors for cancer risk in specific populations: systematic review and meta-analysis.Frontiers in clinical diabetes and healthcare · 2026Pooled it
- An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell lung cancer (SCLC), a therapy-resistant neuroendocrine carcinoma, shows variable responses to immune checkpoint inhibitors (ICIs) and chemotherapy regimens. This study aimed to evaluate the pre-screening utility of peripheral blood serum albumin (ALB) and the glucose-to-lymphocyte ratio (GLR) as biomarkers for identifying populations of SCLC patients likely to benefit from ICIs. Methods: A retrospective cohort of SCLC patients receiving ICIs between 2018 and 2023 was analyzed. The optimal prognostic thresholds for ALB and the GLR were determined using maximally selected rank statistics. The survival outcomes were assessed via Kaplan-Meier analysis and Cox regression. A propensity score matching (PSM) analysis adjusted for confounders was performed. A prognostic nomogram integrating ALB, the GLR, and clinical variables was developed. Model performance was assessed using the concordance index (C-index) and time-dependent receiver operating characteristic (ROC) curves. Results: Among 126 eligible patients, 93 (73.8%) had extensive-stage SCLC at diagnosis, and 33 (26.2%) presented with brain metastasis. The optimal cut-off values of ALB and the GLR for predicting overall survival (OS) were 40.9 g/L and 5.02, respectively. Multivariable Cox regression identified ALB [hazard ratio (HR) =0.415, 95% confidence interval (CI): 0.247-0.696] and GLR (HR =0.560, 95% CI: 0.315-0.994) as independent prognostic factors favoring longer OS, with ALB showing stronger protective association. Patients with both high ALB and a high GLR demonstrated the most favorable OS among the four subgroups (P<0.001). The prognostic model, which incorporated ALB, the GLR, carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and clinical stage, had a C-index of 0.752 [area under the curve (AUC) values: 0.804 at 12 months and 0.781 at 24 months]. Conclusions: Pre-treatment serum ALB and the GLR represent cost-effective, readily accessible biomarkers for stratifying SCLC patients who may derive survival benefits from ICI-based regimens. These findings warrant validation in prospective multicenter studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.